Renalytix plc
("Renalytix" or the "Company")
Grant of Share Options
New York and SALT LAKE CITY, April 22, 2022 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Remuneration Committee has agreed to issue options over a total of 40,000 ordinary shares of 0.25 pence each in the capital of the Company (the "Share Options") to Tim Scannell, a Non-Executive Director of the Company.
The Share Options, which have been issued in line with the Company's existing share option plan, have an exercise price of £2.76 per share, being the price set the recent equity placing. One quarter of the Share Options vest 12 months from the date of grant with one twelfth vesting quarterly after that, subject to Mr. Scannell remaining a Non-Executive Director of the Company. The Share Options have typical acceleration provisions in the event of a change of control of Renalytix.
For further information, please contact:
| Renalytix plc | ||||
| James McCullough, CEO | Via Walbrook PR | |||
| | | |||
| Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |||
| Alex Price / Nicholas Moore | | |||
| | | |||
| Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |||
| Gary Clarence / Daniel Adams | | |||
| | | |||
| Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |||
| Paul McManus / Lianne Applegarth / Alice Woodings | Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 | |||
| | | |||
| CapComm Partners | Tel: 415-389-6400 or investors@renalytix.com | |||
| Peter DeNardo | |
| ||
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Tim Scannell | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Non-Executive Director | |||
| b)
| Initial notification /Amendment
| Initial notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Renalytix plc | |||
| b)
| LEI
| 213800NTOH3FK3WER551
| |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Options over ordinary shares of 0.25 pence each in the Company | |||
| | | ||||
| Identification code | GB00BYWL4Y04 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of options over shares | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | £2.76 | 40,000 | | |
| | | | | | |
| d)
| Aggregated information |
| |||
| | | ||||
| - Aggregated volume | 40,000 | ||||
| | | ||||
| - Price | £110,400 | ||||
| | | ||||
| e)
| Date of the transaction
| 21 April 2022 | |||
| f)
| Place of the transaction
| Outside of trading venue - off market | |||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
